Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ALMR
Alamar Biosciences
$21.96
$22.01
$18.84
$27.20
$1.52BN/A281,190 shs996,564 shs
Mirion Technologies, Inc. stock logo
MIR
Mirion Technologies
$18.50
-0.6%
$18.46
$15.58
$30.28
$4.66B1.034.02 million shs8.56 million shs
10x Genomics stock logo
TXG
10x Genomics
$34.76
$25.61
$10.48
$35.65
$4.41B2.123.18 million shs3.61 million shs
Vontier Corporation stock logo
VNT
Vontier
$29.97
+0.2%
$31.65
$27.25
$48.20
$4.21B1.161.83 million shs3.43 million shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ALMR
Alamar Biosciences
0.00%-0.18%-0.18%+2,195,999,900.00%+2,195,999,900.00%
Mirion Technologies, Inc. stock logo
MIR
Mirion Technologies
0.00%+11.48%+5.29%+0.26%-5.51%
10x Genomics stock logo
TXG
10x Genomics
0.00%+20.53%+40.84%+89.02%+219.78%
Vontier Corporation stock logo
VNT
Vontier
0.00%+2.60%+3.57%-14.76%-16.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ALMR
Alamar Biosciences
$21.96
$22.01
$18.84
$27.20
$1.52BN/A281,190 shs996,564 shs
Mirion Technologies, Inc. stock logo
MIR
Mirion Technologies
$18.50
-0.6%
$18.46
$15.58
$30.28
$4.66B1.034.02 million shs8.56 million shs
10x Genomics stock logo
TXG
10x Genomics
$34.76
$25.61
$10.48
$35.65
$4.41B2.123.18 million shs3.61 million shs
Vontier Corporation stock logo
VNT
Vontier
$29.97
+0.2%
$31.65
$27.25
$48.20
$4.21B1.161.83 million shs3.43 million shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ALMR
Alamar Biosciences
0.00%-0.18%-0.18%+2,195,999,900.00%+2,195,999,900.00%
Mirion Technologies, Inc. stock logo
MIR
Mirion Technologies
0.00%+11.48%+5.29%+0.26%-5.51%
10x Genomics stock logo
TXG
10x Genomics
0.00%+20.53%+40.84%+89.02%+219.78%
Vontier Corporation stock logo
VNT
Vontier
0.00%+2.60%+3.57%-14.76%-16.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ALMR
Alamar Biosciences
2.67
Moderate Buy$30.0036.61% Upside
Mirion Technologies, Inc. stock logo
MIR
Mirion Technologies
2.80
Moderate Buy$27.1346.60% Upside
10x Genomics stock logo
TXG
10x Genomics
2.20
Hold$23.17-33.35% Downside
Vontier Corporation stock logo
VNT
Vontier
2.40
Hold$42.3841.39% Upside

Current Analyst Ratings Breakdown

Latest ALMR, MIR, TXG, and VNT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/26/2026
Vontier Corporation stock logo
VNT
Vontier
DowngradeBuyHold
5/19/2026
Vontier Corporation stock logo
VNT
Vontier
DowngradeHold (C+)Hold (C)
5/18/2026
10x Genomics stock logo
TXG
10x Genomics
DowngradeStrong-BuyHold
5/13/2026
ALMR
Alamar Biosciences
UpgradeHold
5/12/2026
10x Genomics stock logo
TXG
10x Genomics
Boost Price TargetEqual Weight$20.00 ➝ $22.00
5/12/2026
ALMR
Alamar Biosciences
Initiated CoverageBuy$30.00
5/12/2026
ALMR
Alamar Biosciences
Initiated CoverageBuy$28.00
5/12/2026
ALMR
Alamar Biosciences
Initiated CoverageBuy$30.00
5/12/2026
ALMR
Alamar Biosciences
Initiated CoverageNeutral$27.00
5/12/2026
ALMR
Alamar Biosciences
Initiated CoverageOutperform$35.00
5/12/2026
ALMR
Alamar Biosciences
Initiated CoverageOverweight$30.00
(Data available from 6/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ALMR
Alamar Biosciences
$87.16M17.46N/AN/AN/A
Mirion Technologies, Inc. stock logo
MIR
Mirion Technologies
$925.40M5.01$1.08 per share17.19$8.25 per share2.24
10x Genomics stock logo
TXG
10x Genomics
$638.78M6.91N/AN/A$6.24 per share5.57
Vontier Corporation stock logo
VNT
Vontier
$3.08B1.37$4.22 per share7.10$8.84 per share3.39
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ALMR
Alamar Biosciences
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Mirion Technologies, Inc. stock logo
MIR
Mirion Technologies
$28.80M$0.10185.0330.33N/A2.56%6.44%3.48%7/30/2026 (Estimated)
10x Genomics stock logo
TXG
10x Genomics
-$43.54M-$0.17N/AN/AN/A-3.55%-2.86%-2.23%8/6/2026 (Estimated)
Vontier Corporation stock logo
VNT
Vontier
$406.10M$2.8310.598.171.1313.37%37.88%10.90%7/30/2026 (Estimated)

Latest ALMR, MIR, TXG, and VNT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2026Q1 2026
ALMR
Alamar Biosciences
N/A-$1.74N/A-$1.74N/A$26.04 million
5/7/2026Q1 2026
10x Genomics stock logo
TXG
10x Genomics
-$0.29-$0.10+$0.19-$0.10$146.41 million$150.84 million
5/7/2026Q1 2026
Vontier Corporation stock logo
VNT
Vontier
$0.82$0.80-$0.02$0.66$737.21 million$750.60 million
4/28/2026Q1 2026
Mirion Technologies, Inc. stock logo
MIR
Mirion Technologies
$0.09$0.10+$0.01-$0.01$244.78 million$257.60 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ALMR
Alamar Biosciences
N/AN/AN/AN/AN/A
Mirion Technologies, Inc. stock logo
MIR
Mirion Technologies
N/AN/AN/AN/AN/A
10x Genomics stock logo
TXG
10x Genomics
N/AN/AN/AN/AN/A
Vontier Corporation stock logo
VNT
Vontier
$0.100.33%N/A3.53%N/A

Latest ALMR, MIR, TXG, and VNT Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/19/2026
Vontier Corporation stock logo
VNT
Vontier
quarterly$0.02500.35%6/4/20266/4/20266/25/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ALMR
Alamar Biosciences
N/AN/AN/A
Mirion Technologies, Inc. stock logo
MIR
Mirion Technologies
0.63
3.19
2.63
10x Genomics stock logo
TXG
10x Genomics
N/A
5.90
5.42
Vontier Corporation stock logo
VNT
Vontier
1.26
1.23
0.90

Institutional Ownership

CompanyInstitutional Ownership
ALMR
Alamar Biosciences
N/A
Mirion Technologies, Inc. stock logo
MIR
Mirion Technologies
78.51%
10x Genomics stock logo
TXG
10x Genomics
84.68%
Vontier Corporation stock logo
VNT
Vontier
95.83%

Insider Ownership

CompanyInsider Ownership
ALMR
Alamar Biosciences
N/A
Mirion Technologies, Inc. stock logo
MIR
Mirion Technologies
6.30%
10x Genomics stock logo
TXG
10x Genomics
8.84%
Vontier Corporation stock logo
VNT
Vontier
1.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
ALMR
Alamar Biosciences
22269.31 millionN/AN/A
Mirion Technologies, Inc. stock logo
MIR
Mirion Technologies
3,281250.42 million234.64 millionOptionable
10x Genomics stock logo
TXG
10x Genomics
1,240126.96 million115.73 millionOptionable
Vontier Corporation stock logo
VNT
Vontier
7,800140.80 million139.25 millionOptionable

Recent News About These Companies

Vontier Gallops on Gold Award
Vontier: Selling To Shrink

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alamar Biosciences NASDAQ:ALMR

$21.96 0.00 (0.00%)
As of 06/18/2026 04:00 PM Eastern

Our mission is to power precision proteomics to enable the earliest detection of disease. We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. We refer to this combination of features as “Precision Proteomics,” and believe it fills a critical gap in the field of advanced proteomics, enabling researchers to establish the relationship between incremental changes in multiplexed protein biomarkers and the clinically meaningful differences in health, disease and drug therapy. Our integrated platform consists of proprietary instruments, consumables and analytical software that is designed to provide scientists with an end-to-end solution to precisely and consistently measure from one to hundreds of low-abundance and difficult-to-detect biomarkers across the continuum of discovery, translational research and ultimately diagnostics. We commercially launched our proprietary instrument, the ARGO High Throughput (“HT”) System in January 2024 and have already experienced rapid adoption, with more than 300 customers across 25 countries and a cumulative installed base of over 100 instruments with an average annual pull-through greater than $400,000 per instrument for the year ended December 31, 2025. The robust performance of our platform is further evidenced in over 100 scientific publications since our commercial launch. Our customers include top global research and academic institutions, biopharmaceutical companies, contract research organizations and service labs. All ten of the top ten biopharma companies by 2024 revenue are customers of Alamar. We are also developing a second proprietary instrument as part of our IVD platform, called the ARGO HT/DX instrument, for which we intend to provide a submission to the FDA for marketing authorization in 2027. We have established multiple multi-million dollar collaborations with renowned research foundations to help support the development of our ARGO HT/DX instrument and the discovery of biomarkers in neurodegenerative disease. Proteins are essential for all life functions and the fundamental molecules behind healthy cellular operations and the causal mechanisms of disease, as illustrated by the fact that a large majority of effective drugs have proteins as targets. Proteomic analysis has great potential to identify “biomarkers” of health, to characterize disturbances in disease, to discover new drug targets, to assess risks and to measure the impact of interventions such as drugs and lifestyle changes. However, the complexity of disease and biology requires analysis of multiple proteins and pathways at once. As a result of this complexity, much of the human proteome has remained unmeasurable or unquantifiable by other proteomic technologies, and true Precision Proteomics has not been possible. Our proprietary and patented NULISA technology addresses these critical limitations, and we believe it is currently the only platform that enables Precision Proteomics. The chemistry underpinning our technology employs a unique sequential purification of immunocomplexes to suppress background noise and enable the detection of low-abundance protein targets in biofluids across large and diverse populations. Our platform is a fully integrated and fully automated proteomic analysis solution and provides scientists with an end-to-end solution to precisely and consistently measure from one to over one hundred low-abundance and difficult-to-detect biomarkers across the continuum of discovery, translational research, and ultimately, diagnostics. Scientists value our platform because it offers an accessible, easy-to-use and reliable ultra-high sensitivity and multiplexed biomarker analysis of large cohorts of samples. Our current instrument, the ARGO HT System, is designed to fully automate high-sensitivity and high-plex proteomics analysis and is currently available for research use only (“RUO”) applications. It was built to execute our NULISA chemistry in a simple and reproducible workflow for broad biomarker profiling, validation and potential translation into future clinical use. The ARGO HT System facilitates the seamless analysis of large cohorts and clinical research with minimal handling, rapid turnaround times and high data quality. Our initial assay menu focuses on neurology and immunology. We develop a significant portion of our assay panels in close partnership with our customers, who are experts in identifying important protein biomarkers in their respective fields. Our flagship multiplex assay, the CNS Disease Panel 120, provides broad coverage of neurodegeneration pathways. Additionally, our single-plex BD-pTau217 assay can distinctly measure brain-derived-pTau217, which is present in low abundance in blood and is critical for research involving biomarkers for early diagnosis of Alzheimer’s disease. Our assay enables BD-pTau217 quantitation using a small blood sample, offering a noninvasive, economical and convenient alternative to cerebrospinal fluid sample tests or PET scans. We also develop kits for customers to create their own assays, enabling our technology to meet the needs of customers operating in their disease areas of interest. The flexibility of our platform is designed to enable researchers to seamlessly transition from high-plex discovery panels to the development of low-plex diagnostics assays. As a result, our strategy is to continue driving adoption in the targeted discovery and translational markets and subsequently establish a foundation for clinical diagnostics through internal innovation and external collaborations. Ultimately, our platform is designed to support the entire customer journey from discovery to diagnostics, unlocking the full value of precision medicine and early disease detection. We were founded in May 2018 as a Delaware corporation. Our principal executive offices are located in Fremont, California.

Mirion Technologies stock logo

Mirion Technologies NYSE:MIR

$18.50 -0.11 (-0.57%)
Closing price 06/18/2026 03:59 PM Eastern
Extended Trading
$18.55 +0.05 (+0.25%)
As of 06/18/2026 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Mirion Technologies, Inc. provides radiation detection, measurement, analysis, and monitoring products and services in the United States, Canada, the United Kingdom, France, Germany, Finland, China, Belgium, Netherlands, Estonia, South Korea, and Japan. It operates through two segments, Medical and Technologies. The Medical segment offers radiation oncology quality assurance and dosimetry solutions; patient safety solutions for diagnostic imaging and radiation therapy centers; radiation therapy quality assurance solutions for calibrating and verifying imaging and treatment accuracy; and radionuclide therapy products for nuclear medicine applications, such as shielding, product handling, medical imaging furniture, and rehabilitation products. This segment supports applications in medical diagnostics, cancer treatment, practitioner safety, and rehabilitation. The Technologies segment focuses on addressing critical radiation safety, measurement, and analysis applications; and provides personal radiation detection, identification equipment, and analysis tools. The company's products and solutions also include nuclear medicines, dosimeters, contamination and clearance monitors, reactor instrumentation and control equipment and systems, medical and industrial imaging systems and related accessories, alpha spectroscopy instruments, alpha/beta counting instruments, and gamma spectroscopy detector systems; and electrical penetration, cancer diagnostics, software, and other services. It serves hospitals, clinics and urgent care facilities, dental and veterinary offices, radiation treatment facilities, OEMs for radiation therapy, laboratories, military organizations, government agencies, industrial companies, power and utility companies, reactor design firms, and NPPs. The company was formerly known as Global Monitoring Systems, Inc. and changed its name to Mirion Technologies, Inc. in January 2006. The company was incorporated in 2005 and is headquartered in Atlanta, Georgia.

10x Genomics stock logo

10x Genomics NASDAQ:TXG

$34.76 0.00 (0.00%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$34.69 -0.07 (-0.20%)
As of 06/18/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Vontier stock logo

Vontier NYSE:VNT

$29.97 +0.06 (+0.20%)
Closing price 06/18/2026 03:59 PM Eastern
Extended Trading
$29.94 -0.03 (-0.09%)
As of 06/18/2026 04:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vontier Corporation provides mobility ecosystem solutions worldwide. The company operates through Mobility Technologies, Repair Solutions, and Environmental and Fueling Solutions segments. The Mobility Technologies segment provides digitally equipment solutions for mobility ecosystem, such as point-of-sale and payment systems, workflow automation, telematics, data analytics, software platform, and integrated solutions for alternative fuel dispensing. The Repair Solutions segment manufactures and distributes vehicle repair tools, toolboxes, automotive diagnostic equipment and software through mobile franchise network. The Environmental and Fueling Solutions segment offers environmental, fueling hardware, software, and aftermarket solutions for fueling infrastructures. It also offers a range of solutions, including environmental sensors; fueling equipment; field payment hardware; point-of sale, workflow, and monitoring software; vehicle tracking and fleet management; software solutions for EV charging; and vehicle mechanics, and technicians equipment. The company markets its products and services to retail and commercial fueling, convenience store, and car wash operators; commercial vehicle repair businesses, fleet owners/operators and electric vehicle charging network operators, as well as direct sales personnel and independent distributors. It serves customers in North America, the Asia Pacific, Europe, and Latin America. Vontier Corporation was incorporated in 2019 and is headquartered in Raleigh, North Carolina.